Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understanding of the molecular biology grows.
Sagar Lonial, MD, of the Emory University School of Medicine, discusses the importance of planning for relapse based on the treatment a patient has received, new targets for refractory myeloma, and the role of cellular therapy.
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses the challenges of treating high-grade B-cell lymphoma in older patients and those with comorbidities. Several strategies have been devised, but more research is needed as well as more options for novel therapies.
Peggy Burhenn, MS, RN-BC, AOCNS, of the City of Hope National Medical Center, discusses the challenges of working with older lymphoma patients and the importance of effective geriatric assessments.
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses aggressive subtypes of peripheral T-cell lymphoma and the coming data that may help clarify what could be the most effective treatments.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses promising pathways for inhibitors—BTK, PI3K, EZH2, bcl-2—and the clinical trials for single agents and combinations that suggest their potential for lymphoma treatment.
